UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 516

Sortiert nach

An increased tendency in fibrinogen activity and its association with a hypo-fibrinolytic state in early stages after injury in patients without acute traumatic coagulopathy (ATC)

Journal of thrombosis and thrombolysis, 2018-05, Vol.45 (4), p.477-485

2018

Volltextzugriff (PDF)

Fifth Åland Island conference on von Willebrand disease

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-05, Vol.24 (S4), p.5-19

2018

Volltextzugriff (PDF)

Nicotinamide is a potent inhibitor of proinflammatory cytokines

Clinical and experimental immunology, 2003-01, Vol.131 (1), p.48-52

2003

Volltextzugriff (PDF)

Decreased fibrin network permeability and impaired fibrinolysis in the acute and convalescent phase of ischemic stroke

Thrombosis research, 2011-01, Vol.127 (1), p.51-56

2011

Volltextzugriff (PDF)

Validation of a composite score for clinical severity of hemophilia

Journal of thrombosis and haemostasis, 2008-07, Vol.6 (7), p.1113-1121

2008

Volltextzugriff (PDF)

Fibrinogen depletion after plasma-dilution: impairment of proteolytic resistance and reversal via clotting factor concentrates

Thrombosis and haemostasis, 2014, Vol.111 (3), p.417

2014

Volltextzugriff (PDF)

Impaired fibrinolytic capacity and increased fibrin formation associate with myocardial infarction

Thrombosis and haemostasis, 2012-06, Vol.107 (6), p.1092

2012

Volltextzugriff (PDF)

The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX

Journal of thrombosis and haemostasis, 2003-06, Vol.1 (6), p.1215-1219

2003

Volltextzugriff (PDF)

Tranexamic acid – an old drug still going strong and making a revival

Thrombosis research, 2015-02, Vol.135 (2), p.231-242

2015

Volltextzugriff (PDF)

The direct thrombin inhibitors (argatroban, bivalirudin and lepirudin) and the indirect Xa-inhibitor (danaparoid) increase fibrin network porosity and thus facilitate fibrinolysis

Thrombosis and haemostasis, 2010-05, Vol.103 (5), p.1076

2010

Volltextzugriff (PDF)

Preanalytical conditions that affect coagulation testing, including hormonal status and therapy

Journal of thrombosis and haemostasis, 2007-04, Vol.5 (4), p.855-858

2007

Volltextzugriff (PDF)

Inflammatory and haemostatic markers in idiopathic intracranial hypertension

Journal of internal medicine, 2011-11, Vol.270 (5), p.496-499

2011

Volltextzugriff (PDF)

A Simple and Rapid Laboratory Method for Determination of Haemostasis Potential in Plasma: II. Modifications for Use in Routine Laboratories and Research Work

Thrombosis research, 2001-09, Vol.103 (5), p.355-361

2001

Volltextzugriff (PDF)

In vivo roles of factor XII

Blood, 2012-11, Vol.120 (22), p.4296-4303

2012

Volltextzugriff (PDF)

Memories of my research into von Willebrand's disease

Haemophilia : the official journal of the World Federation of Hemophilia, 2012-01, Vol.18 (1), p.3-6

Blomback, M

2012

Volltextzugriff (PDF)

Beneficial effects of dalteparin on haemostatic function and local tissue oxygenation in patients with diabetes, severe vascular disease, and foot ulcers

Journal of vascular surgery, 2008, Vol.47 (5), p.1120-1120

2008

Volltextzugriff (PDF)

Fibrin Network Porosity and Endo-/Exogenous Thrombin Cross-talk

Seminars in thrombosis and hemostasis, 2021-10, Vol.47 (7), p.775

2021

Volltextzugriff (PDF)

Effect of dalteparin on healing of Chronic foot ulcers in diabetic patients with peripheral arterial occlusive disease: A prospective, randomized, double-blind, placebo-controlled study

Diabetes care, 2003-09, Vol.26 (9), p.2575-2580

2003

Volltextzugriff (PDF)

Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age

Thrombosis and haemostasis, 1996, Vol.76 (4), p.535

1996

Volltextzugriff (PDF)

von Willebrand disease biology

Haemophilia : the official journal of the World Federation of Hemophilia, 2012-07, Vol.18 (s4), p.141-147

2012

Volltextzugriff (PDF)

A pharmacokinetic study of dalteparin (Fragmin®) during late pregnancy

Blood coagulation & fibrinolysis, 1998-06, Vol.9 (4), p.343-350

1998

Volltextzugriff (PDF)

Assays of fibrin network properties altered by VKAs in atrial fibrillation - importance of using an appropriate coagulation trigger

Thrombosis and haemostasis, 2015-04, Vol.113 (4), p.851

2015

Volltextzugriff (PDF)

Increased hemostasis potential persists in women with previous thromboembolism with or without APC resistance

Journal of thrombosis and haemostasis, 2003-12, Vol.1 (12), p.2531-2535

2003

Volltextzugriff (PDF)

Monitoring of coagulation factor therapy in patients with von Willebrand disease type 3 using a microchip flow chamber system

Thrombosis and haemostasis, 2017-01, Vol.117 (1), p.75

2017

Volltextzugriff (PDF)

Better increase in fibrin gel porosity by low dose than intermediate dose acetylsalicylic acid

European heart journal, 1998-11, Vol.19 (11), p.1666-1672

1998

Volltextzugriff (PDF)

1 – 25 von 516

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(461)
Mit Volltextzugriff
(340)

Publikationsform

Sprache

Englisch
(493)
Japanisch
(25)
Schwedisch
(22)
Deutsch
(3)

Erscheinungsjahr

n.n

Thema

Humans
(358)
Science & Technology
(307)
Life Sciences & Biomedicine
(294)
Biological And Medical Sciences
(174)
Hematology
(168)
Medicin Och Hälsovetenskap
(164)
Female
(162)
Medical Sciences
(160)
Adult
(142)
Male
(142)
Middle Aged
(124)
Cardiovascular System & Cardiology
(114)
Peripheral Vascular Disease
(108)
Aged
(79)
Fibrinolysis
(64)
Blood Coagulation
(60)
Hematologic And Hematopoietic Diseases
(43)
Adolescent
(37)
Platelet Diseases And Coagulopathies
(37)
Blood Coagulation Tests
(36)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

An increased tendency in fibrinogen activity and its association with a hypo-fibrinolytic state in early stages after injury in patients without acute traumatic coagulopathy (ATC)

Fifth Åland Island conference on von Willebrand disease

Nicotinamide is a potent inhibitor of proinflammatory cytokines

Decreased fibrin network permeability and impaired fibrinolysis in the acute and convalescent phase of ischemic stroke

Validation of a composite score for clinical severity of hemophilia

Fibrinogen depletion after plasma-dilution: impairment of proteolytic resistance and reversal via clotting factor concentrates

Impaired fibrinolytic capacity and increased fibrin formation associate with myocardial infarction

The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX

Tranexamic acid – an old drug still going strong and making a revival

The direct thrombin inhibitors (argatroban, bivalirudin and lepirudin) and the indirect Xa-inhibitor (danaparoid) increase fibrin network porosity and thus facilitate fibrinolysis

Preanalytical conditions that affect coagulation testing, including hormonal status and therapy

Inflammatory and haemostatic markers in idiopathic intracranial hypertension

A Simple and Rapid Laboratory Method for Determination of Haemostasis Potential in Plasma: II. Modifications for Use in Routine Laboratories and Research Work

In vivo roles of factor XII

Memories of my research into von Willebrand's disease

Beneficial effects of dalteparin on haemostatic function and local tissue oxygenation in patients with diabetes, severe vascular disease, and foot ulcers

Fibrin Network Porosity and Endo-/Exogenous Thrombin Cross-talk

Effect of dalteparin on healing of Chronic foot ulcers in diabetic patients with peripheral arterial occlusive disease: A prospective, randomized, double-blind, placebo-controlled study

Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age

von Willebrand disease biology

A pharmacokinetic study of dalteparin (Fragmin®) during late pregnancy

Assays of fibrin network properties altered by VKAs in atrial fibrillation - importance of using an appropriate coagulation trigger

Increased hemostasis potential persists in women with previous thromboembolism with or without APC resistance

Monitoring of coagulation factor therapy in patients with von Willebrand disease type 3 using a microchip flow chamber system

Better increase in fibrin gel porosity by low dose than intermediate dose acetylsalicylic acid

Suchergebnisse filtern